Apellis Pharmaceuticals

Inactive

APLS (NGM)

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes therapies for diseases with high unmet needs. It markets EMPAVELI for paroxysmal nocturnal hemoglobinuria and SYFOVRE for geographic atrophy due to age-related macular degeneration. It also develops APL-3007 siRNA for GA and aims at FcRn-targeted programs, in-house projects, and Beam collaborations. Founded 2009, based in Waltham, MA.